Delivery Order SPE2DB22D7065-SPE2DB25FH3HT
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $4,741.94. This contract is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $14,662.29. This non-competitive delivery order is set to be completed by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,783.60 on May 13, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) by the Defense Logistics Agency. This contract utilizes firm fixed pricing under a non-set-aside, competitively awarded arrangement with an ultimate completion date of May 14, 2025. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $21,423.22 on June 18, 2025, for the supply of Vyvanse Caps 60mg to support the Defense Logistics Agency's Medical Supply Chain. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 20, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to compete on an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $5,486.46. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to this major pharmaceutical distributor. The order is set for ultimate completion on August 8, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed price contract on September 12, 2025, with a ceiling value of $1,337.70 and ultimate completion date of September 15, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor for federal medical procurement, leveraging the company's existing indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $8,072.36 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 18, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DB22D7065Indefinite Delivery Contract
- SPE2DB22D7065-SPE2DB25FH3HTDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,884.22 by the Defense Logistics Agency (DLA) on August 15, 2025, for the supply of Vyvanse 20 mg capsules (100-count units). The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance is scheduled for completion by August 18, 2025, with fulfillment from the contractor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The award reflects AmerisourceBergen's role as a critical pharmaceutical vendor supporting federal medical procurement, particularly for military and veteran healthcare systems. As a major pharmaceutical distributor, the company supplies a comprehensive range of medications and medical supplies across multiple therapeutic domains. Vyvanse, a prescription medication commonly used in military and federal healthcare settings, represents one category within the company's extensive portfolio of brand-name and generic pharmaceuticals delivered through the DLA Medical Supply Chain. This delivery order demonstrates the operational flexibility of the SPE2DX prime vendor contract in fulfilling specific pharmaceutical requirements for federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 8/15/25 |